CC
PLRX icon

Casdin Capital’s Pliant Therapeutics PLRX Stock Holding History

Casdin Capital’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000,000
Closed -$10.8M – 36
2024
Q2 		$10.8M Hold
1,000,000
– – 0.82% 22
2024
Q1 		$14.9M Sell
1,000,000
-577,108
-37% -$9.52M 1.11% 21
2023
Q4 		$28.6M Hold
1,577,108
– – 2.8% 13
2023
Q3 		$27.3M Sell
1,577,108
-122,892
-7% -$2.13M 3.03% 12
2023
Q2 		$30.8M Buy
1,700,000
+25,000
+1% +$592K 2.69% 15
2023
Q1 		$44.6M Hold
1,675,000
– – 3.67% 8
2022
Q4 		$32.4M Buy
1,675,000
+925,000
+123% +$19.3M 2.51% 12
2022
Q3 		$15.7M Buy
+750,000
New +$14.3M 1.03% 21

Other funds holding PLRX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Casdin Capital's PLRX Position: Q3 2024 in Review

Casdin Capital sold out of Pliant Therapeutics (PLRX) in Q3 2024, closing a stake of 1,000,000 shares — an estimated $10.8M sold.

Casdin Capital first reported a position in PLRX in Q3 2022 and held it in 8 quarters. The position peaked at $44.6M in Q1 2023. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • Casdin Capital reported no remaining Pliant Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Casdin Capital sold 1,000,000 Pliant Therapeutics shares in Q3 2024, an estimated $10.8M.
  • Casdin Capital first reported a position in Pliant Therapeutics in Q3 2022 and held it in 8 quarters.
  • Casdin Capital's Pliant Therapeutics position peaked at $44.6M in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on Casdin Capital's 13F filing for Q3 2024, filed 14 Nov 2024.